[1]
Wu, H-Z.; Xiao, J-Q.; Xiao, S-S.; Cheng, Y. KRAS: A promising therapeutic target for cancer treatment. Curr. Top. Med. Chem., 2019, 19(23), 2081-2097.
[2]
Chen, F.; Alphonse, M.P.; Liu, Y. Liu, Q. Targeting mutant KRAS for anticancer therapy. Curr. Top. Med. Chem., 2019, 19(23), 2098-2113.
[3]
Ye, N.; Xu, Q.; Li, W.; Wang, P.; Zhou, J. Recent advances in developing k-ras plasma membrane localization inhibitors. Curr. Top. Med. Chem., 2019, 19(23), 2114-2127.
[4]
He, H.; Xu, C.; Cheng, Z.; Qian, X.; Zheng, L. Drug combinatorial therapies for the treatment of KRAS mutated lung cancers. Curr. Top. Med. Chem., 2019, 19(23), 2128-2142.
[5]
Shao, Y-T.; Ma, L.; Zhang, T-H.; Xu, T-R.; Ye, Y-C.; Liu, Y. The application of the RNA interference technologies for KRAS: current status, future perspective and associated challenges. Curr. Top. Med. Chem., 2019, 19(23), 2143-2157.
Current Topics in Medicinal Chemistry
Title:Drug Discovery by Targeting Mutant KRAS
Volume: 19 Issue: 23
Author(s): Na Ye
Affiliation:
Export Options
About this article
Cite this article as:
Ye Na , Drug Discovery by Targeting Mutant KRAS, Current Topics in Medicinal Chemistry 2019; 19 (23) . https://dx.doi.org/10.2174/156802661923191113144238
DOI https://dx.doi.org/10.2174/156802661923191113144238 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
40
3
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
miR-375 Inhibits the Proliferation, Migration and Invasion of Esophageal Squamous Cell Carcinoma by Targeting XPR1
Current Gene Therapy LncRNAs: Potential Novel Prognostic and Diagnostic Biomarkers in Colorectal Cancer
Current Medicinal Chemistry Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews Analysis of the Concordance in the EGFR Pathway Status Between Primary Tumors and Related Metastases of Colorectal Cancer Patients:Implications for Cancer Therapy
Current Cancer Drug Targets γ-Synuclein is Closely Involved in Autophagy that Protects Colon Cancer Cell from Endoplasmic Reticulum Stress
Anti-Cancer Agents in Medicinal Chemistry Polymorphisms in miRNAs Gene (146a, 149, 196a) and Susceptibility to ARV-associated Hepatotoxicity
Current Genomics Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives
Anti-Cancer Agents in Medicinal Chemistry Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Current Medicinal Chemistry The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Genetic Polymorphisms of Drug Metabolizing Enzymes and Transporters: The Long Way from Bench to Bedside
Current Topics in Medicinal Chemistry A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-Small Cell Lung and Colorectal Cancers: Design, Synthesis, <i>In silico</i> and <i>In vitro</i> Studies Providing Mechanistic Insight into Their Anticancer Potencies
Medicinal Chemistry